Reference health

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

https://doi.org/10.1182/blood.2021014085
CiteStamped reference-health badge
30/30 checkable references clean · checked 2026-07-23

Every reference with a DOI in the deposited reference list resolved to a known work in Crossref or DataCite at the dated check, and none carried a retraction, withdrawal, or removal notice.

3 without a DOI — not checked. A reference deposited without a DOI is never matched by title or guessed at; it stays outside the checked set, and this line discloses that.

The 30 checked references that resolve
resolves10.1038/s41579-020-00459-7
Characteristics of SARS-CoV-2 and COVID-19
resolves10.1016/S0140-6736(20)30183-5
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
resolves10.1001/jama.2021.14811
Confronting the Delta Variant of SARS-CoV-2, Summer 2021
resolves10.1182/blood.2020006965
Outcomes of COVID-19 in patients with CLL: a multicenter international experience
resolves10.1038/s41375-020-0959-x
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
resolves10.1182/blood.2021011841
COVID-19 in patients with CLL: improved survival outcomes and update on management strategies
resolves10.1038/s41375-020-01030-2
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia
resolves10.1182/blood.2021011568
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
resolves10.1016/j.ccell.2021.06.002
Seroconversion rates following COVID-19 vaccination among patients with cancer
resolves10.1038/s41375-021-01270-w
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia
resolves10.1056/NEJMc2108861
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
resolves10.1182/blood-2017-09-806398
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
resolves10.1016/j.chom.2020.06.020
A Replication-Competent Vesicular Stomatitis Virus for Studies of SARS-CoV-2 Spike-Mediated Cell Entry and Its Inhibition
resolves10.1038/sj.leu.2404457
ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia
resolves10.1056/NEJM200012283432602
Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia
resolves10.1016/j.critrevonc.2005.03.012
Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy
resolves10.1023/A:1008389119525
Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma
resolves10.1016/j.ccell.2021.07.012
Antibody response to SARS-CoV-2 vaccines in patients with hematologic malignancies
resolves10.1038/s41408-021-00528-x
Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia
resolves10.3109/10428194.2012.706285
Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia
resolves10.1002/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4
Serum immunoglobulins in B-chronic lymphocytic leukemia.Natural history and prognostic significance
resolves10.1016/j.vaccine.2007.10.053
Antibody response to 7-valent conjugated pneumococcal vaccine in patients with chronic lymphocytic leukaemia
resolves10.1056/NEJMc2110716
Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination
resolves10.1038/s41408-021-00534-z
Weak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignancies
resolves10.1056/NEJMoa2109072
Covid-19 Breakthrough Infections in Vaccinated Health Care Workers
resolves10.1038/s41591-021-01386-7
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
resolves10.1101/2021.08.24.21262423
Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel
resolves10.1038/s41591-021-01377-8
Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
resolves10.1056/NEJMc2113468
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
resolves10.1056/NEJMoa2114255
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
The 3 references without a DOI — listed, not checked
no DOI — not checkedCOVID-19 in patients with chronic lymphocytic leukemia: clinical outcome and B- and T-cell immunity during 13 months in consecutive patients
no DOI — not checkedClinical management of COVID-19: interim guidance
no DOI — not checkedSafety and efficacy of BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
What this badge says. CiteStamped means the CHECKABLE references of this work were clean at the dated check: each resolved to a known work in a public registry, and none carried a retraction notice at that time. It says nothing about the quality, findings, or importance of the work itself, and nothing about references deposited without a DOI.

checked 2026-07-23 — re-checked daily as this page is visited; titles and statuses come from Crossref and DataCite and are not part of the signed record

Embed this badge

Both snippets point at the live badge image and link back to this page. The badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.

<a href="https://citestamp.com/citestamped/10.1182/blood.2021014085"><img src="https://citestamp.com/citestamped/10.1182/blood.2021014085/badge.svg" alt="CiteStamped reference-health badge" width="460" height="64"></a>
[![CiteStamped reference-health badge](https://citestamp.com/citestamped/10.1182/blood.2021014085/badge.svg)](https://citestamp.com/citestamped/10.1182/blood.2021014085)